Please ensure Javascript is enabled for purposes of website accessibility
Accessibility Menu
Verve Therapeutics Stock Quote

Verve Therapeutics (NASDAQ: VERV)

Price as of March 4, 2024, 12:37 p.m. ET

You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Verve Therapeutics Return vs. S&P

1 Year 5 Year 5 Year Annualized Since IPO
VERV -19.20% -49%
S&P +29.03% +83.23% +12.86% +22%

Verve Therapeutics Company Info

Verve Therapeutics, Inc. is a genetic medicines company, which engages in the development of approach to the care of cardiovascular disease. The company was founded by Sekar Kathiresan, Kiran Musunuru, Keith J. Joung, Issi Rozen, Sekar Kathiresan, Burt A. Adelman, and Barry Ticho in 2018 and is headquartered in Boston, MA.

News & Analysis


Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.